1. Volume 14, Issue 3, Pages 199-209 (March 2013)
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial 
Prof Ajay Vora, FRCPath, Nick Goulden, PhD, Rachel Wade, MSc, Chris Mitchell, FRCPCH, Jeremy Hancock, PhD, Rachael Hough, MD, Clare Rowntree, PhD, Sue Richards, DPhil 
The Lancet Oncology 
Volume 14, Issue 3, Pages (March 2013)
DOI: /S (12)
Copyright © 2013 Elsevier Ltd Terms and Conditions

2. Figure 1
Outline of treatment regimens for clinical risk groups defined by National Cancer Institute criteria, cytogenetics, and early response
IM=interim maintenance. DI=delayed intensification. BFM=Berlin–Frankfurt–Munster. MRD=minimal residual disease. MRD low-risk patients assigned to one delayed intensification receive DI1 and then receive continuing therapy. MRD high-risk patients assigned to the intensive schedule transferred to clinical high-risk regimen after induction.
The Lancet Oncology  , DOI: ( /S (12) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

3. Figure 2
Trial profile
MRD=minimal residual disease. *One patient had Burkitt's lymphoma, one T-cell lymphoma, one T non-Hodgkin lymphoma, one mature B-cell acute lymphoblastic leukaemia, two acute myeloid leukaemia, five mixed-phenotype acute leukaemia, and one precursor B non-Hodgkin lymphoma. †Results not reported here; longer follow-up necessary. ‡No patients lost to follow-up before 1 year or excluded from analysis.
The Lancet Oncology  , DOI: ( /S (12) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

4. Figure 3
Event-free survival, relapse, and overall survival in the trial overall
The Lancet Oncology  , DOI: ( /S (12) )
Copyright © 2013 Elsevier Ltd Terms and Conditions

5. Figure 4 Event-free survival and relapse in MRD low-risk patients
MRD=minimal residual disease.
The Lancet Oncology  , DOI: ( /S (12) )
Copyright © 2013 Elsevier Ltd Terms and Conditions